JERUSALEM (Reuters) – Israeli drugmaker Kamada said on Monday it extended an agreement with Baxter International to supply a drug to treat emphysema through 2017. Under the extended agreement, Kamada said it will receive $26 million in additional revenues of Glassia, a proprietary drug…
Source:Kamada extends emphysema drug deal with Baxter through 2017
Monday, September 29, 2014
Kamada extends emphysema drug deal with Baxter through 2017
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment